STAAR Surgical Company
STAAHealthcareNASDAQMedical Instruments & Supplies · Last scanned Sep 8, 2026
Scan Results
Daily timeframeSTAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the. The company carries a $1.18B market cap, placing it firmly in the small-cap category. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Market Cap
$1.18B
Beta
1.22
P/E (TTM)
293.38
P/E (Fwd)
22.93
EPS (TTM)
$0.08
EPS (Fwd)
$1.02
ROE
1.1%
ROA
5.7%
Cash
$181.5M
Total Debt
$35.9M
Free CF
$15.3M
52W Change
-15.2%
Annual Financials
Cash vs Debt
Where STAA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, STAA finished 4.39% below its 150-day moving average ($24.17) and 3.99% below its 200-day moving average ($24.07). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is STAA overbought or oversold?
At the September 3, 2026 close, STAA's RSI(14) was 36.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
STAAR Surgical Company holds $181.5M in cash against $35.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $15.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 1.1%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has pulled back from $284.4M (2022) to $239.4M (2025), a 16% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. At over 50x earnings, STAA carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing STAA.